Menu

Caffeine-Triggered Cells Help Control Blood Sugar in Diabetic Mice

Scientists engineered human cells to produce a molecule that stimulates insulin secretion in the presence of caffeine.

Jun 20, 2018
Diana Kwon

PIXABAY, ALEXAS_FOTOS

Scientists have engineered human cells that boost the production of insulin in response to caffeine. These modified cells could one day help treat patients with type 2 diabetes, researchers suggested in their report, published yesterday (June 19) in Nature Communications.

“You could completely integrate this into your lifestyle,” study coauthor Martin Fussenegger, a biotechnologist at the Swiss Federal Institute of Technology in Zurich, tells The Guardian. “You have a tea or coffee in the morning, another after lunch, and another at dinner, depending on how much drug you need to get your glucose back down.”

Fussenegger and his colleagues engineered human embryonic kidney cells that produce a synthetic version of human glucagon-like peptide 1 (GLP-1), a molecule that prompts the release of insulin, in the presence of caffeine.

Then, the team injected diabetic mice with an implant containing hundreds of the engineered cells. This revealed that the animals’ blood-sugar levels could be controlled by simply adding a caffeinated beverage, such as coffee, cola, or Red Bull, to their meals. Noncaffeinated beverages, such as herbal tea and chocolate milkshakes, had no effect.

Such implants are unlikely to be accidently triggered by other foods or beverages, Fussenegger tells New Scientist. “[V]ery small trace amounts of caffeine will not trigger the system,” he says.

Although the technique is still in the early stages of development, if it proves to be safe and effective in humans, it could one day replace insulin injections, Fussenegger tells The Guardian. “You could have your normal life back,” he says. “The implant could last for six months to a year before it would need to be replaced.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!